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1. INTRODUCTION 
Humans have known breast cancer for a very long time. For those who think, 
Breast cancer is a modern disease, they would be surprised to know that the 
disease can be tracked right back to 3000 – 2500 B.C where medical texts made 
by Edwin Smith Papyrus describes cases of breast cancer. And Hippocrates 
described the stages of breast cancer as early as 400 BC. 
In the first century AD, doctors experimented with surgical incisions to destroy 
tumors.They thought breast cancer was due to end of menstruation and thus 
came the concept of attributing malignancies to old age. 
The renaissance saw the revival of surgery & doctors began exploring human 
bodies.John hunter was the one who identified lymph as cause of breast cancer 
spread.It`s both ironical &tragical that an exposed organ with easy access to 
self-examination& clinical diagnosis continues to exhort such a heavy toll. 
The frequency of this disease in women has prompted an intensive study of risk 
factors that develop breast cancer to gain cues to its etiology as well as to 
identify risk factors that would be helpful for prevention strategies. 
With the advent of multimodality treatment approach, number of cancer 
survivors are increasing which push us further to increase our knowledge on 
potential sites which could be exploited for the survival benefit of the patients. 
Insulin resistance has long been known to be a risk factor in various 
malignancies including breast, colon& endometrium. Insulin, a member of 
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family of growth factors that includes insulin like growth factors IGF 1,IGF II 
,exerts mitogenic effects on normal and mitogenic breast epithelial cells acting 
via insulin &IGF 1 receptors. Insulin resistance leads to over expression of the 
above mentioned receptors & malignant transformation of cells. 
Recent studies have shown that treatment with  metformin  reduce insulin 
resistance  and  showed complete pathological response & less local recurrence 
& distant metastasis 
Reliable data on insulin resistance in our population is scarce and its association 
with breast cancer is still a matter of debate which needs further analysis. Hence 
we felt the need for the study in our setting. 
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2. AIM OF THE STUDY 
 
1. To assess the prevalence of insulin resistance in non-diabetic carcinoma 
breast patients 
2. To document fasting insulin levels in the same cohort of patients 
3. To observe the  clinical pattern & pathological  characteristics of disease 
in patients with insulin resistance. 
4. To aid in further studies to assess the pharmaco therapeutic use of 
Metformin in carcinoma breast patients with insulin resistance, with the 
analyzed results. 
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3. REVIEW OF LITERATURE 
 
In a study conducted by  IRCCS  ,Istituto Di Ricovero e Cura a Carattere 
Scientifico (IRCCS) , a principal institution of Italian research & health care, in 
2015 by Nicoletta Provinciali, Matteo Puntoni et al   116 patients of carcinoma 
breast were included to assess insulin resistance & 46.95 % of them were found 
to be insulin resistant with  poor survival rate. These data suggest that host 
metabolic status might influence the prognosis of  breast cancer treated and 
therefore additional alternative strategies, targeting host metabolism, should be 
considered in this unfavorable subset of patients.  
 
A study was conducted  by the Department of Epidemiology and Population 
Health, Albert Einstein College of Medicine, Bronx, New York, in  2009, by 
Marc J. Gunter, Donald R. Hoover et al ,comprising of 1800 patients. Their data 
indicate that hyperinsulinemia and high endogenous estradiol levels are 
independent risk factors for postmenopausal breast cancer and largely explain 
the association between obesity and the risk of breast cancer in postmenopausal 
women.  
 
In a study conducted by Department of Pharmacology and Toxicology, School 
of Medicine, University of Sarajevo, Bosnia and Herzegovina by Kusturica 
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J, Kulo Ćesić A   in 2017 ,234 patients were included.Tthe study revealed 
metformin use as a single independent predictor of patients , 
 while metformin use was shown to be a significant independent predictor 
(OR=0.049; 95% CI=0.013-0.181; p=0.001).Our findings support the 
hypothesis that the use of metformin compared to the use of other oral 
antidiabetic drugs is associated with a lower risk of cancer in patients with 
increased insulin resistance. 
 
A study conducted by wenzhou medical university, china. In july 2017 by Jiali 
Zhang,Gefei Li et al, Metformin Inhibits Tumorigenesis and Tumor Growth of 
Breast Cancer cells in vitro cell lines. 
 
In a study conducted by Sanggeun Nam, Seho Park et al, From the Department 
of Surgery, Yonsei University College of Medicine, Seoul, Korea in 2016, 760 
non diabetic cancer breast patients were included, out of which 26.4% showed 
insulin resistance and was associated with larger tumours. These findings 
suggest that insulin resistance could mechanistically induce tumor progression 
and might be a good prognostic factor, and that it could represent a therapeutic 
target in postmenopausal patients with breast cancer 
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In a study conducted by Alvino et al, at The University of Adelaide, Adelaide, 
Australia, in 2011 ,the mechanism of insulin on invitro cells were studied and it 
showed the kinase activity of ILP receptors, leading to the phosphorylation of 
IR substrates in the cell membrane, which in turn  activates phosphoinositide 3-
kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), 
PI3K/Akt/forkhead box O (FoxO), and Ras/MAPK/extracellular signal-related 
kinase 1/2 (ERK-1/2) pathways, whose important roles in cancer cell growth 
and carcinogenesis have been reported . 
 
A study conducted by  Pamela J. Goodwin et al, at Samuel Lunenfeld Research 
Institute, Mount Sinai Hospital; Toronto-Sunnybrook Regional Cancer Centre 
in 2002, in which a cohort of 512 patients with cancer breast were prospectively 
analysed with fasting insulin levels. It showed that a patient with insulin 
resistance had poor outcomes & hence the need to explore effective treatment 
strategies. 
3.1.CARCINOMA BREAST 
Breast  cancer  is  the  most common cancer diagnosed and the second leading 
cause of cancer mortality in women. Major advances in recent years, including 
hormonal and monoclonal antibody therapy, have greatly improved outcomes in 
breast cancer patients 
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3.1.1EMBRYOLOGY OF BREAST 
The mammary glands are modified and highly specialized sweat glands and 
therefore develop from the surface ectoderm. 
 The development occurs as follows:  
● In the fourth week, the surface ectoderm thickens on either side of the ventral 
aspect of trunk of embryo along the line extending from the axilla to the 
inguinal region to form mammary ridge or line. 
● About 15–20 mammary buds develop as solid down growths of the epidermis 
into the underlying mesenchyme along the mammary ridge on each side. 
 ● Normally mammary ridge and  mammary buds disappear, except in the 
pectoral region. 
 ● In the pectoral region, the mammary bud presents a surface depression called       
mammary pit.  
● About 15–20 epithelial cords grow inwards from the bottom of the pit into the 
underlying dermis. The epithelial cords are primordia of lactiferous ducts. 
 ● The deeper ends of the epithelial cords subdivide further and terminate as 
ampullated ends—the primordia of ductules and alveoli.  
● At the end of fetal life, the epithelial cords and their branches are canalized 
and form lactiferous ducts. 
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 ● Initially the lactiferous ducts open into the bottom of the mammary pit. 
 ● Shortly before birth the pit is evaginated by the growth of underlying 
mesoderm and form the nipple.  
● The rudimentary mammary glands of new born males and females are similar. 
This condition persists throughout life in males. In females, however, infantile 
form of mammary gland grows in size at puberty under the influence of sex 
hormones and assumes a hemispherical outline. The full development of breast 
occurs at about 19 years of age. 
 
3.1.2.SURGICAL ANATOMY OF BREAST 
The  adult  female  breast  or  mammary gland lies in the subcutaneous tissue 
(superficial fascia) of the anterior thoracic wall. Despite individual variations, 
the extent of the base of the breast is almost constant, from the sternal edge to 
the midaxillary line, and from the second to sixth ribs. It overlies pectoralis 
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major, overlapping onto serratus anterior and a small part of the rectus sheath 
and external oblique muscle.  
 
 
A small part of the upper outer quadrant may be prolonged towards the axilla. 
This extension (the axillary tail) usually lies in the subcutaneous fat; rarely it 
may penetrate the deep fascia of the axillary floor and lie adjacent to axillary 
lymph nodes. Some 15–20 lactiferous ducts, each draining a lobe of the breast, 
converge in a radial direction to open individually on the tip of the nipple, the 
projection just below the centre of the breast which is surrounded by an area of 
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pigmented skin, the areola. Each lactiferous duct has a dilated sinus at its 
terminal portion in the nipple.  
 
Smooth muscle cells are present in the nipple and their contraction causes 
erection of the nipple. Large sebaceous glands, sweat glands and other areolar 
glands are present in the skin of the areola. The areolar glands form small 
elevations (tubercles of Montgomery), particularly when they enlarge during 
pregnancy.  
Behind the breast the superficial fascia (the upward continuation of the 
membranous layer of superficial abdominal fascia of Scarpa) is condensed to 
form a posterior capsule. Strands of fibrous tissue (forming the suspensory 
ligaments of Cooper) connect the dermis of the overlying skin to the ducts of 
the breast and to this fascia. Between the capsule and the fascia over pectoralis 
major is the loose connective tissue of the retromammary space. 
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BLOOD SUPPLY 
 The blood supply of breast is from internal thoracic artery, a branch of 1st part 
of subclavian artery which supplies medial aspect of breast. 
Lateral part receives blood supply from pectoral branches of thoraco acromial 
artery,lateral thoracic artery ,branch of axillary artery. 
Lateral perforator branches of posterior intercostal artery(2nd,3rd,4th ) & few 
unnamed branches from anterior intercostal artery. 
VENOUS DRAINAGE: 
• Internal mammary vein 
• Lateral thoracic vein which drains into axillary vein 
• Lateral perforator branch which drains into intercostal veins,in turn to 
vertebral vein & plexus – BATESON’S PLEXUS, the main route of bone 
metastasis. 
LYMPHATIC DRAINAGE 
• Sub areolar plexus of lymphatics communicates with lymphatics within 
the breast.  
• Around 75% of the lymphatic drainage of the breast passes to axillary 
lymph nodes, mainly to the  
• Anterior nodes – along lateral thoracic vein  
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• Posterior nodes – posterior axillary fold along subscapular vessels 
• Lateral nodes – upper part of humerus along axillary vein. 
• central nodes – upper part of axillary pad of fat. 
• Apical – superior to central group of nodes. 
• Much of the rest of the lymphatic drainage, originating particularly from 
the medial part of the breasts, is to internal mammary nodes along the 
internal thoracic artery. 
The superficial lymphatics of the breast have connections with those of the 
opposite breast and the anterior abdominal wall, from the extra peritoneal 
tissues of which there is drainage through the diaphragm to posterior 
mediastinal nodes. Direct drainage from the breast to inferior deep cervical 
(supraclavicular) nodes is possible. These minor pathways tend to convey 
lymph from the breast only when the major channels are obstructed by 
malignant disease 
3.1.3.NORMAL DEVELOPMENT AND PHYSIOLOGY 
In the United States, puberty, as measured by breast development and the 
growth of pubic hair, begins between the ages of 9 and 12 years,and menarche 
(onset of menstrual cycles) begins at approximately 12 to 13 years of age. These 
events are initiated by low-amplitude pulses of pituitary gonadotropins, which 
increase serum estradiol concentrations. 
18 
 
In the breast, this hormone-dependent maturation (thelarche) entails increased 
deposition of fat, the formation of new ducts by branching and elongation, and 
the first appearance of lobular units. This process of growth and cell division is 
under the control of estrogen, progesterone, adrenal hormones, pituitary 
hormones, and the trophic effects of insulin and thyroid hormone. 
The post pubertal mature or resting breast contains fat, stroma, lactiferous ducts, 
and lobular units. During phases of the menstrual cycle or in response to 
exogenous hormones, the breast epithelium and lobular stroma undergo cyclic 
stimulation. The dominant process appears to be hypertrophy and alteration of 
morphology rather than hyperplasia. In the late luteal (premenstrual) phase, 
there is an accumulation of fluid and intralobularedema 
With pregnancy, there is diminution of the fibrous stroma and the formation of 
new acini or lobules, termed adenosis of pregnancy. After birth, there is a 
sudden loss of placental hormones, which, combined with continued high levels 
of prolactin, is the principal trigger for lactation. 
The actual expulsion of milk is under hormonal control and is caused by 
contraction of the myoepithelial cells that surround the breast ducts and terminal 
ductules. There is no evidence for innervation of these myoepithelial cells; their 
contraction appears to occur in response to the pituitary-derived peptide 
oxytocin. 
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Stimulation of the nipple appears to be the physiologic signal for continued 
pituitary secretion of prolactin and acute release of oxytocin. When 
breastfeeding ceases, the prolactin level decreases and there is no stimulus for 
release of oxytocin. The breast returns to a resting state and to the cyclic 
changes induced when menstruation resumes. 
 
3.1.4.Relative risk of invasive breast carcinoma based on pathological 
examination of benign breast tissue (American College of Pathologists ) 
No increased risk   
Adenosis,  
sclerosing or ﬂorid Apocrine metaplasia  
Cysts, macro and/or micro  
Duct ectasia 
Fibroadenoma 
Fibrosis Hyperplasia 
Mastitis(inﬂammation) Periductal mastitis 
Squamous metaplasia  
Slightly increased risk (1.5–2 times)  
20 
 
Hyperplasia, moderate or ﬂorid, solid or papillary  
Papilloma with a ﬁbrovascular core  
Moderately increased risk (5 times) 
Atypical hyperplasia (ductal or lobular)  
Insufﬁcient data to assign a risk 
Solitary papilloma of lactiferous sinus 
Radial scar lesion 
Aetiology 
• Carcinoma breast is more common in developed, western countries.  
• It is second most common carcinoma in females. Incidence is 19-34%. 
Median age is 47 years 
Risk factors:  
1. Genetic factors: 
• BRCA 1 & BRCA 2 gene mutation 
• Cowdens syndrome 
• Li- Fraumeni syndrome 
• BRCA 3 &p53 mutation 
• Ataxia telengiectasia 
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2. Obesity 
3 . Family history of breast cancer, uterine/ovarian/colonic cancers. 
4. Previous therapeutic radiation (thoracic) 
5 . Diet low with phytoestrogens and high alcohol intake have high-risk       
of breast cancer. Vitamin C reduces the risk.  
6. Benign breast diseases with atypia, hyperplasia and epitheliosis has 
got higher risk in a patient with family history. RR in nonproliferative 
ﬁ brocystic disease is 1.0; proliferative without atypia is 1.5; 
proliferative with atypia is 4.0 (with family history 6.5, 
premenopausal 6.0) 
Hormonal factors: 
➢ Increased estrogen exposure - nulliparous woman,early menarche, 
late menopause 
➢ Late ﬁrst child birth after 35 yrs. 
➢ Hormone replacement therapy > 5 yrs 
Incidences in carcinoma breast 
➢ 30% of all female cancers  
➢ 20% of cancer related deaths in females  
➢ 2-4% bilateral  2-5% hereditary  
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➢ Lump in the breast—most common presentation (75%)   
➢ 10% presents with pain  
➢  35-45% with mutation of BRCA1 gene   
➢ 70% blood spread occurs to bones  
Risk factors classiﬁcation 
Slight to moderate risk 
• Florid hyperplasia 
• Solid duct papilloma 
• Obesity, alcohol, HRT 
• Nulliparity 
• Early menarche, late menopause 
Moderate to high-risk 
• Age > 60 years  
• ATD / ALS/ LCIS 
• History of DCIS  
• Cancer on one side breast 
Very high-risk 
•  Therapeutic radiation 
• Family history of breast cancer in two 1st degree relatives  
• Family history of breast and ovarian cancer  
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• BRCA1 and BRCA2 mutation carrier or 1st degree relative with 
mutation 
3.1.5.CLASSIFICATION OF PRIMARY BREAST CANCER  
Carcinoma in situ  
LCIS(Lobular carcinoma in situ) 
DCIS (Ductal carcinoma in situ ) 
Invasive carcinoma 
➢ Paget's disease of the nipple 
➢ Invasive ductal carcinoma 
o Invasive ductal with NST (no special type) -70% 
o Medullary carcinoma – 4% 
o Tubular carcinoma—2% 
o mucinous —2% 
o Invasive cribriform—2% 
o Invasive papillary—1% 
Mixed connective tissue and epithelial   
o Phyllodes, 
o angiosarcoma, 
o carcinosarcoma 
DCIS (DUCTAL CARCINOMA IN SITU) 
 It is intraductal proliferation of malignant mammary ducal epithelial cells 
without any invasion into the basement membrane.   
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 It can be:  
• Solid& comedo (high grade) 
• Cribriform& papillary (low grade) 
• Micropapillary.  
 It is associated with high expression of C – erb2 gene (80%). 
 In 20% of cases synchronous invasive carcinoma in duct is seen.   
Untreated DCIS becomes invasive in > 50% cases (5 fold).   
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NOTTINGHAM PROGNOSTIC INDEX (NPI): 
( 0.2 × Tumour size in cm) + Lymph node stage + Tumour grade  
 NPI score—< 3.4     Good prognosis with 80%  survival (15 years) 
 NPI score—3.4 –5.4  Moderate prognosis with 40% survival  
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 NPI score—> 5.4    Poor prognosis with 15% survival 
TYPES OF CARCINOMA BREAST 
1. Scirrhous carcinoma: 
❖ 60% .  
❖ hard, whitish, or whitish yellow, noncapsulated, irregular, with 
cartilaginous consistency.  
     2. Medullary carcinoma (5%):  
❖ Also called as ‘encephaloid type’ because of its brain like 
consistency.  
❖ It contains malignant cells with dispersed lymphocytes 
2. Inﬂammatory carcinoma/Lactating carcinoma/Mastitis 
carcinomatosis:  
❖ Most aggressive type of carcinoma breast. 
❖ It is 2% common.   
❖ common in pregnancy & lactation.   
❖ mimics acute mastitis   
❖ rapidly progressive tumour  
❖ Treatment includes external radiotherapy and chemotherapy.   
❖ Salvage surgery whenever possible. worst prognosis.   
4. Colloid carcinoma: 
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It produces abundant mucin, both intraandextracellularly carrying better 
prognosis. 
 5. Paget’s disease of the nipple  
❖ It is superﬁcial manifestation of an intraductal carcinoma.  
❖ The malignancy spreads within the duct up to the skin of the nipple 
and down into the sub stance of the breast.  
❖ It mimics eczema of nipple and areola. 
6. Tubular, papillary, cribriform are other types of duct carcinomas. 
 7. Atrophic scirrhous carcinoma. 
 8. Lobular carcinoma in situ: 
❖ It originates in terminal duct lobular unit .    
❖ It is multifocal, bilateral (50%).   It is an incidental pathological entity.  
❖ Classical type carries better prognosis; pleomorphic type does not so; 
occasionally mixed ductal and lobular in situ may be seen.  
Immunohistochemistry using  e-cadherin antibody shows positive 
reaction in lobular carcinoma.  
 9. Disease of Reclus: 
❖ It is a rare intracysticpapilliferous carcinoma of breast presenting as a 
cystic swelling with bloody discharge from the nipple. 
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GRADING OF THE TUMOUR 
It can be  
Grade-1   well-differentiated  
Grade -2  moderately differentiated  and  
Grade -3 poorly differentiated . 
ELSTON-ELLIS MODIFIED BLOOM-RICHARDSON GRADING 
SYSTEM 
Parameters used : 
1) Nuclear pleomorphism:  
Score1—relatively small uniform nuclei;                                                                                                                        
score 2—intermediate pleomorphic nucleoli; 
score 3—relatively large prominent nucleoli  
2) Mitotic count:  
Score 1—< 10% mitoses in 10 HPF; 
score 2—10-20% mitoses; 
score 3—>20% mitoses   
3) Tubule formation: 
 Score 1—>75% cells in tubule forms;  
score 2—10-75% cells in tubule forms;  
score 3—< 10% cells in tubule forms 
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GRADE SCORE 
Favourable         1 
Unfavourable      Up to 3 
Grade I                3-5 
Grade II              6-7 
Grade III            8-9 
  
  
  
 
Well differentiated low grade -grade 3, 4, 5  
 Moderately differentiated intermediate grade-grade 6, 7  
 Poorly differentiated high grade-8, 9  
BIOLOGICAL BEHAVIOUR AND CLINICAL FEATURES OF 
CARCINOMA BREAST  
✓ clinically palpable breast lump- commonly in upper outer quadrant 
✓ nipple retraction & discharge 
✓ skin changes(tethering,puckering,dimpling,retraction of nipple) 
✓ peau d’orange,skin ulceration & nodules 
✓ fixity to underlying muscle & chest wall 
✓ enlargement of lymph nodes 
✓ distant spread 
• Chest pain and haemoptysis   
• Bone pain, tenderness, and pathological fracture  
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• Pleural effusion, ascites  
• Liver secondaries, secondary ovarian tumour    
CAUSES OF LYMPHATIC BLOCK IN CARCINOMA BREAST 
 Involvement and ﬁxation of the axillary nodes level I, II and III 
 After levels I, II and III dissection 
 After radiotherapy to axilla  
 Inoperable ﬁ xed nodes in axilla  
 Recurrent axillary disease  
 associated with cancer-en-cuirasse 
 Secondary infection Effects of lymphatic obstruction  
 Peaud’orange • Brawny oedema of arm- indurated, painful, nonpitting-
occurs in     ﬁxed nodes in axilla 
 Elephantiasis chirurgens- after radical mastectomy or radiotherapy to 
axilla  
 Cancer-en-cuirasse- seen in locally advanced carcinoma of breast. Skin 
of chest wall is studded with hard ﬁxed nodules like armour coat (of 
soldiers)  
 Lymphangiosarcoma after radical mastectomy or MRM (Stewart-
Treve’s) 
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HAEMATOGENOUS SPREAD 
Common sites of distant spread in carcinoma breast 
➢ Bones—70% (lumbar vertebrae, pelvic bones, long bones)  
➢ Lungs and pleura—20-30%  
➢ Soft tissues—5-15%  
➢ Liver—10-12%  
➢ Brain—2-5%  
➢ Adrenals—2-5% 
Transcoelomic  Spread Through mediastinal lymph nodes, it may spread into 
peritoneal cavity causing secondaries in liver, peritoneum, ovary 
(Krukenbergsecondaries—occurs in menstruating age groups. During ovulation, 
cells get attached over the ovarian capsule). 
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3.1.6.STAGING 
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REGIONAL LYMPH NODES (N) 
 
 
DISTANT METASTASIS(M) 
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3.1.7.SELECTION OF SURGICAL THERAPY   
Mastectomy and breast-conserving therapy have been shown to be 
equivalent in terms of patient survival, and the choice of surgical 
treatment is individualized. Patients who desire breast conserving surgery 
must be willing to attend postoperative radiation therapy sessions and to 
undergo postoperative surveillance of the treated breast.. 
In patients with large tumours for whom adjuvant (postoperative) 
systemic chemotherapy will likely be recommended, the use of 
preoperative chemotherapy may be considered. Chemotherapy 
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administered before surgery may decrease the tumour size sufficiently to 
permit breastconserving surgery in patients who would not otherwise 
appear to be good candidates. 
Another strategy is to consider local tissue rearrangement or 
pedicledmyocutaneous flaps (latissimusdorsi) to fill the defect resulting 
from breast-conserving surgery. Patients with multicentrictumors are 
usually served best by mastectomy because it is difficult to perform more 
than one breast-conserving surgery in the same breast with acceptable 
cosmesis. Although high nuclear grade, presence of lymphovascular 
invasion, and negative steroid hormone receptor status all have been 
linked to increased local recurrence rates, none of these factors are 
considered contraindications to breast conservation. 
Surgeries for Carcinoma Breast 
Total (simple) mastectomy:  The breast tissue ,tumour,fat along with 
pectoral fascia removed without axillary clearance. 
Total mastectomy with axillary clearance:   Total mastectomy is done 
along with removal of axillary Level I and II nodes. 
Modiﬁed radical mastectomy [MRM]: 
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Patey’s operation: It is total mastectomy with clearance of all levels of 
axillary nodes and removal of pectoralis minor muscle.  
Nerve to serratus anterior, nerve to latissimusdorsi, intercostobrachial 
nerve, axillary vein, cephalic vein and pectoralis major muscle are 
preserved. Wound is closed with a suction drain.  
Scanlon’s operation: Is a modiﬁedPatey’s operation wherein instead of 
removing pectoralis minor, it is incised to approach the affected level III 
lymph nodes.  
Auchincloss modiﬁed radical mastectomy: Here pectoralis minor muscle 
is left intact and level III lymph nodes are not removed—commonly done 
now. 
 Halsted Radical Mastectomy (Complete Halsted): Structures removed 
are:  
• Tumour.  
• Entire breast, nipple, areola, skin over the tumour with margin.   
• Pectoralis major and minor muscles.   
• Fat, fascia, lymph nodes of axilla.  
• Few digitations of serratus anterior. 
Structures retained are (ABC) 
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• Axillary vein  
• Bells nerve (nerve to serratus anterior)  
• Cephalic vein  
CONSERVATIVE BREAST SURGERIES: 
Wide local excision: Tumour is removed along with one cm clearance. 
Pectoral fascia is usually not opened in wide local excision unlike in total 
mastectomy. And axillary dissection is carried out through separate 
incision. 
The specimen  is marked after placing in orientation grid and 
mammography of the specimen is done followed by frozen section biopsy 
to look for clearance. At least 1 mm clearance is needed for adequacy. 
Margins where clearance is less than 1 mm need re-excision at that 
particular margin.  
Quadrantectomy: It is removal of entire segment/ quadrant with ductal system 
with 2-3 cm normal breast tissue clearance along with axillary dissection (level 
I and II) through separate incision and RT to breast area. 
Toilet mastectomy:  In locally advanced tumour, tumour with breast tissue and 
whatever possible is removed to prevent further fungation. But its use and 
signiﬁcance is under question. It is often done after giving chemotherapy.  
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Extended radical mastectomies:  It includes radical mastectomy + removal of 
internal mammary lymph nodes of same side with or without opposite side. It is 
not done at present. 
Skin sparing mastectomy (SSM/Key hole mastectomy) is becoming popular 
with different approaches.   
Complications of MRM/mastectomy 
• Injury/thrombosis of axillary vein  
• Seroma—50-70%  Shoulder dysfunction 10%  
• Pain (30%) and numbness (70%)   
• Flap necrosis/infection   
• Lymphoedema (15%) and its problems   
• Axillary hyperaesthesia (0.5-1%)  
• Winged scapula   
• Occasionally if on table injury occurs to axillary vein, it should be 
repaired by   vascular suturing using 5 zero polypropylene  
• Numbness over the medial upper part of the arm can occur due to 
intercostobrachial nerve injury  
• Pectoral muscles atrophy if medial and lateral pectoral nerves are 
injured   Weakening of internal rotation and abduction of shoulder 
occurs due to injury to thoracodorsal nerve 
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• Lymphangiosarcoma (Stewart-Treve’s syndrome) of upper limb can 
devel op in patients who have developed lymphoedema after 
mastectomy with axillary clearance. Usually it occurs 3-5 years after 
development of lymphoedema. Such patient may require fore-quarter 
amputation. It has got poor prognosis. It presents as multiple 
subcutaneous nodules. 
Radiotherapy in Carcinoma Breast 
Indications:  Patient who undergo conservative breast surgery, breast is 
irradiated after surgery. 
Radiotherapy in carcinoma breast  
To chest wall 
• T3 tumour >5 cm 
• Residual disease-LABC   
• Positive margin/close surgical margin of < 2 cm   
• After conservative surgery   
• Higher risk group  
• Inﬂammatory carcinoma      
To axilla   
• 4 or more nodes positive 
• Extranodal spread 
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• Axillary status not known/not assessed 
o RT is a must after conservation of breast  
o Local as well as to axilla 
o Tangential ﬁelds 50 Gy/25 fractions/5 weeks  
o Another 10 Gy to tumour bed 
o Internal mammary and supraclavicular area may be included in radiation 
ﬁeld 
o External radiotherapy is given over the breast area, axilla (in selected 
patients like if axillary dissection is not done or more than 4 positive 
axillary nodes), internal mammary and supraclavicular area   
o Total dosage 5000 cGY units  
o 200-cGY units daily 5 days a week for 6 weeks 
HORMONE THERAPY IN CARCINOMA BREAST 
 Principles:  It is used in ER/PR positive patients in all age group. 
i. Hormone therapy reduces the recurrence rate and so probably improves 
the life span and quality of life, which includes, 
ii. Oestrogen receptor antagonists—tamoxifen. 
iii. Ovarian ablation by surgery (Bilateral oophorectomy) or by radiation. 
iv. LHRH agonists (Medical oophorectomy). 
v. Oral aromatase inhibitors for postmenopausal women. 
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vi. Adrenalectomy or pituitary ablation. 
vii. Progesterone receptor antagonist. 
viii. Androgens—Inj testosterone propionate 100 mg IM three times a week.   
ix. Aminoglutethimide—blocks the synthesis of steroids by inhibiting 
conversion of cholesterol to pregnenolone— medical adrenalectomy.   
x. Progestogens, e.g. medroxyprogesterone acetate. 
Tamoxifen 
• It is an antioestrogen. It blocks cytosolic oestrogen receptors.  
• Dose is 10 mg BID or 20 mg OD for 5 years.  
• Half life of tamoxifen is 7 days; it takes 4 weeks to show its beneﬁts. It 
reduces the cholesterol and also cardiovascular morbidity.  
• Adverse effects:  are ﬂushing, tachycardia, sweating, genital itching, 
vaginal atrophy and dryness (premenopausal), vaginal discharge 
(postmenopausal), ﬂuid retention, weight gain.  
• It increases the incidence of endometrial cancer.  
• DVT (3%), pulmonary embolism, CVA, TIA, cataract, fractures. Side 
effects and endometrial cancer are less in selective drugs like raloxifene. 
Advantages:  
Selective oestrogen antagonists 
• Do not cause endometrial hyperplasia or endometrial carcinoma.  
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• Drugs include droloxifen, toremifen, raloxifene 
Letrozole 
• It is a nonsteroidal competitive inhibitor of the enzyme ‘aromatase’. This 
enzyme converts adrenal androgens to oestrogen (aromatization). So it is 
an aromatase inhibitor.   
• Other aromatase inhibitors are anastrozole and exemestane (in 
postmenopausal). It is expensive but more effective than tamoxifen. It is 
also used in recurrent disease.   
• Letrozole is used as an adjuvant endocrine therapy in postmenopausal 
women with hormone sensitive breast  
Transtuzumab 
It is a monoclonal antibody that blocks HER-2/Neu receptors thereby  
preventing growth of cancer cells. It is a new drug. It is presently marketed 
as herceptin. It is c-ErbB2 (growth factor receptor) inhibitor. It is a newer 
biological agent. Her 2/Neu receptor is tyrosine kinase receptor.  
 
Chemotherapy in Carcinoma Breast 
❖ Adjuvant chemotherapy 
❖ Neoadjuvant chemotherapy 
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REGIMENS 
CMF regime                        CAF regime                                     MMM regime 
Cyclophosphamide      Cyclophosphamide                                 Methotrexate 
Methotrexate     Adriamycin             Mitomycin-C  
5-Fluorouracil                       5-Fluorouracil                                    Mitozantrone 
 
❖ Toxic effects are: Alopecia, bone marrow sup pression, cystitis, 
megaloblastic anaemia, GIT disturbances, nephritis.  
❖ CMF and CAF are commonly used with monthly/3 weeks cycles for 6 
months.   
❖ Other anthracyclines like doxorubicin or epirubicin should be used often 
for better result.   
❖ Taxanes: They are newer chemotherapeutic drugs which act by G2/M 
phase of cell cycle. It is commonly used in metastatic carcinoma of 
breast. Drugs are paclitaxel and docetaxel. Taxanes have no cross-
resistance with anthracyclines and so can be used sequentially or 
concurrently with anthracyclines.   
❖ Gemcitabine is also used often in selected cases for better results. 
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3.2 INSULIN RESISTANCE 
Insulin has been shown to have mitogenic properties and anti-apoptotic effects 
,in several cancers including breast cancer.Circulating insulin levels is 
associated with increased cancer risk and prognosis. In insulin resistance, there 
is an up regulation of receptors. Diabetes is has found to have an increased risk 
for breast cancer as summarized by Larsson et al 
 
 
 
 
 
 
 
 
 
Insulin is a peptide hormone secreted by the β cells of the pancreatic islets of 
Langerhans and maintains normal blood glucose levels by facilitating cellular 
glucose uptake and promoting cell division and growth through its mitogenic 
effects. 
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Insulin resistance is defined where a normal or elevated insulin level produces 
an attenuated biological response;classically this refers to impaired sensitivity to 
insulin mediated glucose disposal. 
Compensatory hyperinsulinaemia occurs when pancreatic β cell secretion 
increases to maintain normal blood glucose levels in the setting of peripheral 
insulin resistance in muscle and adipose tissue. 
Insulin resistance syndrome refers to the cluster of abnormalities and related 
physical outcomes that occur more commonly in insulin resistant individuals. 
Given tissue differences in insulin dependence and sensitivity, manifestations of 
the insulin resistance syndrome are likely to reflect the composite effects of 
excess insulin and variable resistance to its actions. 
Metabolic syndrome represents the clinical diagnostic entity identifying those 
individuals at high risk with respect to the (cardiovascular) morbidity associated 
with insulin resistance. 
Insulin resistance  is believed to be manifest at the cellular level via post-
receptor defects in insulin signalling. Despite promising findings in 
experimental animals with respect to a range of insulin signalling defects, their 
relevance to human insulin resistance is presently unclear. Possible mechanisms 
include down-regulation, deficiencies or genetic polymorphisms of tyrosine 
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phosphorylation of the insulin receptor, IRS proteins or PIP-3 kinase, or may 
involve abnormalities of GLUT 4 function.33 
The following study shows a poor outcome and increased local and distal 
recurrence in patients witn carcinoma breast who were found to have increased 
insulin resistance as documented by fasting insulin levels.Furthermore, in this 
cohort, insulin was a strong adverse prognostic factor – risk of death was tripled 
and risk of distant recurrence doubled in women whose fasting insulin levels 
were in the highest quartile – these effects persisted after adjustment for tumour, 
treatment related variables and BMI.Goodwin PJ et al. J Clin Oncol 
2002;20:42-51 
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 Obesity is a proven and well documented risk factor for malignancies including 
cancer breast. The common factor being insulin resistance and consequent 
hyperinsulinemia. Insulin  can promote tumourogenesis  directly by affecting 
epithelial tissues or indirectly by affecting the levels of other modulators such as 
insulin like growth factors. 
Insulin resistance is a pathological condition characterized by a decrease in 
efficiency of insulin signaling for blood sugar regulation. Insulin resistance is a 
major component of metabolic syndrome, i.e. a group of risk factors that 
generally occur together and increase the risk for various diseases, including 
type 2 diabetes mellitus and several other metabolic diseases, cerebrovascular 
and coronary artery diseases, neurodegenerative disorders, infectious diseases 
and cancer.  
Due to the ongoing worldwide epidemic of obesity and other insulin resistance-
related disorders, insulin-like peptides (ILPs), i.e. evolutionary conserved and 
ubiquitous factors historically involved in the regulation of energy metabolism, 
have been the subject of thorough investigations. In humans, ILPs include 
insulin, IGF1, IGF2, and seven relaxin-related peptides, which share the same 
basic fold.  
Insulin signal transduction occurs through two insulin receptor (IR) isoforms 
resulting from transcriptional alternative splicing: the ‘A’ isoform (IR-A) that 
recognizes insulin and IGFs, with a greater affinity for IGF2 than IGF1, and the 
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IR ‘B’ isoform (IR-B), which is insulin specific and mainly involved in glucose 
homeostasis. In healthy individuals, blood glucose concentrations are 
maintained within narrow physiological range by a state of balance between 
insulin production by specialized pancreatic β-cells and insulin-mediated 
glucose uptake in target tissues. 
Evidence of  insulin resistance in classic insulin-target organs, together with the 
associated hyperglycemia and hyperinsulinemia are the pathological hallmark of 
metabolic disorders such as obesity and type 2 diabetes is compelling. Several 
population-based studies revealed a decrease in cancer risk in diabetic patients 
assuming antidiabetic agents of the biguanide family such as metformin. 
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On the other hand, a growing body of evidence indicates an association between 
type 2 diabetes and an increase in risk of developing breast, prostate, colon, 
endometrial, and ovarian cancers. 
 
 
 
 
Data obtained from independent studies involving Drosophila model show that 
ILPs have specialized functions including regulating cell proliferation, 
differentiation, survival, and apoptosis, thus playing a pivotal role in cell fate 
determination and life span control. Such functions are evolutionarily 
conserved, and accordingly, the stimulation of IGF1 axis may represent a 
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common medium for both cancer and diabetes pathogenic processes, together 
with systemic inflammation and the associated increase in cytokine production. 
 
 
 
 
Except for the IGF2 receptor (IGF2R), following ligand binding, the kinase 
activity of ILP receptors is activated, leading to the phosphorylation of IR 
substrates in the cell membrane, which in turn  
i) activates phosphoinositide 3-kinase (PI3K)/protein kinase B 
(Akt)/mammalian target of rapamycin (mTOR), PI3K/Akt/forkhead box O 
(FoxO), and Ras/MAPK/extracellular signal-related kinase 1/2 (ERK-1/2) 
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pathways, whose important roles in cancer cell growth and carcinogenesis have 
been reported and 
 ii) inactivates glycogen synthase kinase 3β (GSK3β), the inhibitor of the 
oncogenic β-catenin signaling, through PI3K/Akt signaling pathway, resulting 
in β-catenin signaling activation that has been associated with cancer stemness 
and chemoresistance. Other ILP receptors include the IGF1 receptor (IGF1R) 
that recognizes both IGF1 and IGF2; holoreceptors made up of combinations of 
half IGF1R and IR isoforms or other tyrosine kinases; and finally the IGF2R 
that recognizes only IGF2and attenuates IGF2 signaling by clearing the ligand 
from cell surface without signal transduction. IGFs also bind to carrier proteins 
named IGF-binding proteins’ (IGFBP). 
ILP receptors are structurally related tyrosine kinase receptors. Canonical 
insulin receptor isoform ‘A’ (IR-A), isoform ‘B’ (IR-B), IGF1 receptor 
(IGF1R), and hybrid receptor (holoreceptors made of combinations of half 
IGF1R and IR isoforms or other tyrosine kinases) signaling are mediated 
through downstream pathways like phosphoinositide 3-kinase (PI3K)/protein 
kinase B (Akt)/mammalian target of rapamycin (mTOR), PI3K/Akt/forkhead 
box O (FoxO), Ras/MAPK/extracellular signal-related kinase 1/2 (ERK-1/2) 
pathways, or through PI3K/Akt-mediated inactivation of glycogen synthase 
kinase 3β (GSK3β) that results in the accumulation of β-catenin and in the 
activation of its downstream targets. The IGF2 receptor (IGF2R) attenuates 
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IGF2 signaling by clearing that molecule from the cell surface without signal 
transduction. Overexpression of IGF1R signaling and downregulation of IGF2R 
are commonly reported in cancer, as well as the overexpression of IR-A and 
hybrid receptor signaling in the presence of abnormally high levels of insulin 
and IGFs. 
 
Contrary to insulin, IGFs are produced by many cell types, although the liver is 
their main site of production. IGF1 production in the liver is stimulated by GH, 
IGFs have characteristics of both hormones and tissue growth factors, and 
consequently, they can induce both local and systemic responses. Tissues that 
classically respond to IGFs preferentially express the IGF1R, and nonclassic 
target tissues including cancer cells express both the latter receptor and IR-A 
genes and may display hybrid receptors as well, which probably account in 
carcinogenesis and chemoresistance. 
3.2.1.ILPS, INSULIN RESISTANCE, AND CANCER RISK 
Data sustaining an association between IGF1 and cancer risk include recent 
studies from in elderly, which have suggested that genetic variations in the 
insulin/IGF1 pathway genes are associated with longevity, dementia, metabolic 
diseases, and cancer. 
Insulin resistance as documented by  IGF1 and IGF1/IGFBP3 molar ratio might 
increase mammographic density and thus the risk of developing breast cancer. 
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In familial breast cancer, an association between IGF1 levels and cancer 
development has been reported and IGF1 may predict higher risk of recurrence 
in breast cancer survivors. 
Associations of IGF1 and IGF1/IGFBP3 ratio with mortality in women with 
breast cancer have also been reported. 
3.2.2.ENERGY BALANCE, INSULIN RESISTANCE, AND CANCER 
RISK 
More recent studies have revealed that diets leading to weight gain and 
hyperinsulinemia increase the expression of IR-A on cancer cells, indicating 
that insulin level changes can mediate the effects of energy balance in a recent 
meta-analysis assessed the correlation between intentional weight loss and 
cancer risk reduction. 
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It has been hypothesized that abnormally high levels of growth factors, 
adipokines, reactive oxygen species, adhesion factors, and pro-inflammatory 
cytokines observed under conditions of insulin resistance create a favorable 
niche for neoplastic tissue survival and cancer stem cell development, with 
tumors behaving like ‘wounds that never heal’ to ensure their maintenance. 
Considering that in most cases both cancer incidence and levels of circulating 
cancer biomarkers drop relatively rapidly following intentional weight loss. The 
latter should be further investigated as a meaningful approach for cancer risk 
reduction. 
Although there are controversial data, recent findings, mostly from population-
based studies, have pointed out a link between glucose metabolism, insulin 
levels, and cancer risk.  
A recent meta-analysis of observational studies has revealed that insulin 
resistance is a significant risk factor for endometrial cancer, particularly when 
associated with high levels of circulating adipokines like adiponectin, leptin, 
and plasminogen activator inhibitor-1, as well as androgens and inflammatory 
mediators It is widely accepted that diabetic patients have relatively increased 
cancer risk as well as worse cancer prognosis, in comparison with individuals 
without diabetes. However, a recent study involving 25 476 patients with type 2 
diabetes ,experimental data indicate the overexpression of ILP observed in these 
patients as a cancer risk factor. 
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 The hyperinsulinemia resulting from the body's attempt to compensate insulin 
resistance may benefit fully insulin-sensitive cancer tissue by substantially 
increasing their growth through IR-A/IGF1R increased signaling. Whereas 
some reports indicate that tumors respond favorably to ILP over expression. 
 
Studies evaluating insulin secretion, as reflected by C-peptide levels, have 
pointed out a correlation between high plasma concentration of insulin and poor 
clinical outcome and death in prostate cancer.  
 
 
 
Most recent reports have also suggested that insulin has mitogenic and anti-
apoptotic effects in endometrial cancer, and the activation of IR-A, IR substrate 
1, and Akt is associated with aggressive features.. 
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In lung and breast cancers, an association between the marked expression of 
phosphorylated/activated IGF1Rs and poor clinical outcome has been reported 
A study revealed that the insulin analog glargine displays higher proliferative 
and anti-apoptotic effects than insulin in the breast cancer cell line MCF-7, 
probably through IR-A/IGF1R hybrids. 
Recent evidence indicates that IGF2R plays a crucial role in cancer prevention 
attributed to its antagonist role on cellular growth and evidence of loss of 
heterozygosity in several cancers including breast cancer.  
Loss of function mutations in the gene encoding for this receptor were reported 
in various cancers, including hepatocellular carcinoma; breast carcinoma; 
endometrial, gastric, and colorectal cancers; squamous cell carcinoma; and 
ovarian cancer.  
RNA interference with the expression of the bioactive complex mannose-6-
phosphate (M6P)/IGF2R in urokinase-type plasminogen activator (uPA) or uPA 
receptor (uPAR) expressing human cancer and endothelial cells results in 
increased pericellular plasminogen activation, cell adhesion, and higher invasive 
potential, and M6P/IGF2R silencing also leads to the cell surface accumulation 
of urokinase and plasminogen, as well as an enhanced expression of alpha V 
integrin, indicating that M6P/IGF2R controls cell invasion by regulating alpha 
V integrin expression and by accelerating uPAR cleavage.  
57 
 
Moreover, overexpressed IGF2 can mediate carcinogenic effects through IR-A 
.Notably, IGFs originate from both local and systemic productions in cancer and 
are commonly expressed by cancer cells performed quantitative proteomics of 
insulin-A substrates recruited to tyrosine-phosphorylated protein complexes 
following either insulin or IGF2. 
Conversely, insulin induced significant receptor internalization following signal 
transduction whereas IGF2 induced only a modest internalization. Overall, the 
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study observations suggested that the lower affinity of IGF2 for the receptor, 
which causes a less powerful activation of early downstream effectors in 
comparison with insulin, also protects the receptor and its substrates from 
downregulation, thereby resulting in sustained mitogenic stimuli. 
 
3.2.3.INSULIN RESISTANCE, IMMUNE RESPONSE ALTERATIONS, 
AND CANCER 
ILP molecules have been reported to play a crucial role in altered inflammatory 
responses to infectious challenge commonly observed in insulin resistance-
related metabolic disorders. Experimental evidence suggests that the abnormally 
high number of inflammatory cells in adipose tissue of obese subjects and type 
2 diabetes patients may promote systemic inflammation and a 
microenvironment favorable for neoplastic cell survival and proliferation. 
Experimental data sustaining this theory also include early reports indicating an 
improvement of immune response following gastric bypass and weight loss, and 
recent reports indicating that a high-fat diet increases aberrant angiogenesis, 
solid tumor growth, and lung metastasis of CT26 colon cancer cells, even in 
obesity-resistant BALB/c mice, and comparable studies indicating that 
decreased systemic IGF1 in response to calorie restriction modulates murine 
tumor cell growth, NF-κB activation, and inflammation-related gene 
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expression105. In addition, adipocyte-released IGF1 is regulated by glucose and 
fatty acids and controls breast cancer cell growth in vitro. 
Moreover, the activation of the IGF1R and IR-A signaling target mTOR 
accounts for at least part of the enhancing effects of obesity on mammary tumor 
growth, and such effects are reversed by the mTOR inhibitor RAD001 in mouse 
models of obesity. Besides, macrophages express leptin receptors, which play a 
crucial role in the innate immune response, particularly through activation of 
JAK–STAT signaling pathway, which is the canonical cytokine receptor 
signaling pathway, and through activation of ILP signaling downstream targets 
like PI3K/Akt/mTOR/p70S6K and MAPK/ERKs pathways. 
Leptin triggers the production of pro-inflammatory factors, such as TNF-α, IL1, 
IL6, and leukotriene B4 that normally result in the increase of immune cell 
survival, maturation, and proliferation. However, the drastically increased levels 
of circulating leptin characteristic of obesity and type 2 diabetes may cause cell 
adherence and pathogen recognition impairments instead and probably 
contribute to the occurrence of abnormally increased levels of pro-inflammatory 
factors in these pathological conditions. 
Notably, insulin resistance treatment improves some indices of immune 
response both in experimental models and in patients. Recent clinical studies 
involving patients with morbid obesity and type 2 diabetes mellitus have 
revealed a reduction in endotoxemia, oxidative stress, systemic inflammation, as 
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well as insulin resistance following gastric bypass surgery. Recent findings in 
monocytes from obese subjects, where insulin resistance is associated with 
increases in oxidative stress and activation of pro-inflammatory signaling 
molecules like c-Jun NH (2)-terminal kinase (JNK) and nuclear factor κB 
inhibitor kinase (IKK-β), indicate that the induction of stress kinase inhibitors 
such as heat-shock proteins (Hsp) 72 and Hsp27 improves insulin signaling via 
inhibition of stress kinases and the reduction of serine 
phosphorylated/inactivated IR substrate. 
3.2.4.INSULIN RESISTANCE, INFECTION, AND CANCER 
In the last decades, a substantial body of evidence from humans and animal 
models has indicated a link between insulin resistance and impaired immune 
response to infectious challenges. The deregulation of pathogen recognition in 
insulin resistance-associated conditions and diseases induce the body to trigger 
a sustained inflammatory response against mutualistic microorganism of the 
intestinal gut, such as the stomach common bacterium Helicobacter pylori. 
In addition, silent infection with H. pylori is a source of pro-inflammatory 
cytokines and IGF1 in hyperinsulinemia conditions. Unraveling the precise role 
of ILP molecules in H. pylori-related carcinogenesis may provide novel 
pharmacological targets for microorganism-related cancers. 
Interestingly, a recent clinical study has provided evidence for metabolic 
syndrome in nonobese and nondiabetic patients with chronic hepatitis C virus 
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genotype 1 infection; this metabolic syndrome was associated with overweight, 
increased abdominal fat, hypertension, and insulin resistance.  
3.2.5.INSULIN RESISTANCE AND CANCER TREATMENT 
ILP signaling via the PI3K/Akt/mTOR pathway is a potential therapeutic target 
for many cancer types, including breast and prostate cancers.  Many drug 
candidates targeting ILPs have entered clinical trials, and ILP targeting appears 
to be a promising anticancer strategy.  
 
Cixutumumab, another MAB specifically targeting IGF1R, is relatively safe and 
enhances the tumor growth inhibitory and pro-apoptotic effects of several 
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chemotherapeutics.  However, hyperglycemia and hyperinsulinemia have been 
reported in some patients, together with increases in GH secretion, indicating 
pituitary gland attempts to compensate for the lack of IGF1 signaling feedback. 
Compensatory increases in IR-A following IGF1R silencing and altered insulin 
B expression resulting respectively in chemoresistance and perturbations in 
glucose homeostasis were reported as well. 
The downstream targets of the canonical ILP signaling include the survival 
pathway PI3K/Akt that can activate downstream targets like mTOR and 
FoxO/BAD/Bcl-2 but also inhibit GSK3β, resulting in the activation of the 
oncogenic β-catenin signaling pathway. In the last decade, PI3K, Akt, mTOR, 
FoxO, BAD, Bcl-2, β-catenin, and other signaling molecules involved in cell 
survival and proliferation have been the subjects of investigation of many 
studies aiming at unraveling carcinogenic mechanisms. 
Recent population-based studies have consistently suggested a strong link 
between antidiabetic treatment with drugs of the biguanide family and a 
decrease in cancer incidence and mortality. 
3.2.6.MEASUREMENT OF INSULIN RESISTANCE 
Quantifying insulin sensitivity/resistance in humans and animal models is of 
great importance for basic science investigations and eventual use in clinical 
practice. 
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Measurement of the fasting insulin level has long been considered the most 
practical approach for the measurement of insulin resistance. It correlates well 
with insulin resistance. A considerable correlation has been found between 
fasting insulin levels and insulin action as measured by the clamp technique. 
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NORMAL VALUES: 
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4. MATERIALS AND METHODS: 
This is a prospective study conducted in the DEPARTMENT OF GENERAL 
SURGERY, GOVERNMENT STANLEY MEDICAL COLLEGE  from October 2016 
to  September 2017. 
 
This study includes all patients diagnosed as carcinoma breast, who is a non-
diabetic. The relevant details collected includes clinical, radiological, 
pathological and biochemical profile of patients with carcinoma breast. 
 
 
 
4.1. METHOD OF COLLECTION OF DATA 
• Details of cases,full history,menstrual status, clinical examination 
findings 
• Histopathological report 
• Grading 
• Receptor status [ estrogen , progesterone, her-2 neu receptor ] 
• Fasting glucose levels 
• Fasting insulin levels -  venous sample taken after overnight fasting and 
levels are obtained using insulin assays. 
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4.2. INCLUSION CRITERIA: 
  Patients with pathologically proven carcinoma breast  
 
4.3. EXCLUSION CRITERIA: 
1. Excluded were patients who are known case of diabetes mellitus & found to 
be   diabetic during the course of evaluation. 
 2. Male patients with carcinoma breast 
 
 
 
4.4. SAMPLE SIZE: 
All patients admitted in our  DEPARTMENT  O F GENERAL  SURGERY , 
GOVERNMENT STANLEY MEDICAL COLLEGE ,  from October 2016 to  
September 2017 ,  according to inclusion criteria- Carcinoma breast patients 
who are non-diabetic will be included in the study. 
 
4.5. TYPE OF STUDY: 
 Prospective time bound study 
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5.RESULTS 
DEMOGRAPHIC PROFILE & STATISTICS: 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D 
were used for continuous variables.  
Statistics 
  AGE 
FASTING 
INSULIN 
LEVELS FBS 
N Valid 29 29 29 
Missing 0 0 0 
Mean 49.66 12.237 89.10 
Median 48.00 7.690 89.00 
Std. Deviation 12.022 13.3197 11.143 
Range 44 51.2 43 
Minimum 32 2.3 71 
Maximum 76 53.5 114 
 
 
The following parameters are analysed and tabulated & discussed. 
• Prevalence of insulin resistance. 
• Fasting blood glucose levels. 
• Age wise distribution 
• Size of the lesion 
• Quadrant involved 
• Laterality 
• Staging 
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• Grade of tumour 
• Menstrual status 
• Receptor status 
• Treatment details 
• Age comparison with staging 
• Grade comparison with stage of the tumour 
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DEMOGRAPHIC PROFILE 
RESULTS: 
Following parameters are analysed with the available data. 
1.PREVALENCE 
 
    FASTINGINSULINLEVELS 
  Frequency Percent 
Valid < 25 24 82.8 
> 25 5 17.2 
Total 29 100.0 
 
In our study, the prevalence of insulin resistance is 17.2%. Five patients out of 
29 of our study group has fasting insulin levels > 25µIU/L and found to have 
insulin resistance , with blood glucose levels within normal range. 
 
 
24, 82.8%
5,
17.2%
FASTING INSULIN LEVELS
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FASTING  BLOOD SUGAR LEVELS: 
 
 
 
 
FBS 
  Frequency Percent 
Valid 71 - 80 7 24.1 
81 - 90 9 31.0 
91 - 100 8 27.6 
Above 100 5 17.2 
Total 29 100.0 
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AGE WISE DISTRIBUTION:
 
 
         AGE WISE DISTRIBUTION 
 
  age no of pts percent 
Valid 31-40 8 27.6% 
  41-50 10 34.48% 
  51-60 6 21% 
  61-70 3 10.30% 
  >70 2 6.90% 
 
The incidence of carcinoma breast in this study was maximum in the age group 
of 41-50, with increased incidence in the fourth decade as well with youngest 
being 32 years and maximum age being 72.The incidence of carcinoma breast 
was increasing in younger age group women as well. 
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SIZE OF THE LESION (T – STAGING) 
 
 
In our study, majority of the patients had T3 lesion, with an almost equal 
incidence of T2. The incidence of T1 lesion is almost nil, which might 
indirectly indicate the lack of identification of carcinoma breast at an earlier 
stage inspite of wide spread screening tests & campaign. 
 
 
 
 
 
 
T1
T2
T3
T4
0
11 12
5
SIZE OF THE LESION
Series 1
73 
 
 
LATERALITY 
 
 
Laterality was found to be almost equal between both sides, with a slight 
increase in left sided lesion 
 
SIDE 
  Frequency Percent 
Valid LEFT 15 51.7 
RIGHT 14 48.3 
Total 29 100.0 
 
 
SIDE
LEFT RIGHT
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QUADRANT  INVOLVED: 
 
 
 
QUADRANT 
  Frequency Percent 
Valid LOWER 
INNER 
1 3.4 
RETRO 
AREOLAR 
4 13.8 
UPPER 
INNER 
5 17.2 
UPPER 
OUTER 
19 65.5 
Total 29 100.0 
 
Upper outer quadrant was found to be the commonest involved 
quadrant(65.5%) 
0 5 10 15 20
LOWER INNER
RETRO AREOLAR
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MENSTRUAL STATUS 
 
MENSTRUALSTATUS 
  Frequency Percent 
Valid POSTMENOPAUSAL 17 58.6 
PREMENOPAUSAL 12 41.4 
   
Total 29 100.0 
 
58.6% of the malignancy has occurred in post menopausal women. 
 
 
 
 
 
 
PREMENOPAUSAL
41%
POSTMENOPAUSAL
59%
0%
MENSTRUAL STATUS
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GRADE 
 
 
HISTOPATHOLOGY 
  Frequency Percent 
Valid GRADE I 1 3.4 
GRADE II 1 3.4 
GRADE II 
INVASIVE 
23 79.3 
GRADE 
III 
INVASIVE 
4 13.8 
Total 29 100.0 
 
23 out of 29 patients had GRADE II invasive cancer accounting to almost 80 %. 
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STAGING 
 
STAGING 
  Frequency Percent 
Valid II    A 4 13.8 
II   B 7 24.1 
III   A 12 41.4 
III  B 4 13.8 
IV 2 6.9 
Total 29 100.0 
 
 
 
 
In our study group, stage IIIA more common (41.4%), followed by IIB (24.1%) 
 
 
Stages
II III IV0 2 4 6 8 10 12
II    A
II   B
III   A
III  B
IV
Stages
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TREATMENT DETAILS: 
 
 
 
TREATMENT DETAILS 
  Frequency Percent 
Valid MRM 11 37.9 
MRM/PALLIATION 1 3.4 
NEOADJUVANT 13 44.8 
NEOADJUVANT/MRM 3 10.3 
PALLIATIVE 1 3.4 
Total 29 100.0 
 
   
 
The study cohort shows, majority of the patient(55.1%) as diagnosed in stage 
III, underwent neoadjuvant chemotherapy for down staging of the disease. 
11
1
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3
1
0 2 4 6 8 10 12 14
MRM
MRM/PALLIATION
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PALLIATIVE
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RECEPTOR STATUS : 
 
 
 
TRIPLE NEGATIVE 
  Frequency Percent 
Valid OTHERS 19 65.5 
TRIPLE 
NEGATIVE 
10 34.5 
TOTAL 29 100.0 
 
 
In our study,incidence of  triple negative breast cancers is found to be 34%,  
 
which is higher when compared to other studies. 
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34%
TRIPLE NEGATIVE
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HER 2 neu POSITIVITY 
 
 
The incidence of HER 2 neu positivity was found to be 31%. 
 
 
 
 
HER 2 neu STATUS 
 
 
her2neu 
  Frequency Percent 
Valid NEGATIVE 20 69.0 
POSITIVE 9 31.0 
Total 29 100.0 
 
 
 ER,PR & HER 2 neu STATUS : 
 
The histopathological & immunohistochemistry of the biopsy specimen of the  
 
study population revealed the following pattern of results 
 
✓ ER   - 48.3 % POSITIVITY 
✓ PR   - 31% POSITIVITY 
✓ HER 2 neu – 31 % POSITIVITY 
POSITIVE , 9, 31%
NEGATIVE, 20, 69%
, 0, 0%
, 0, 0%
HER 2 neu
POSITIVE
NEGATIVE
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AGE COMPARISON WITH STAGING. 
 
 
AGE COMPARISON WITH STAGING 
AGE STAGE II STAGE III 
 STAGE 
IV 
31-40 3 4 1 
41-50 4 6 0 
51-60 2 3 1 
>60 
 
TOTAL 
2 
 
11 
3 
 
16 
0 
 
2 
 
 
In our study , most of the patients fall into STAGE III ( 55.12%),followed by 
STAGE II. 
STAGE II, 3
STAGE II, 4
STAGE II, 2 STAGE II, 2
STAGE III, 4
STAGE III, 6
STAGE III, 3 STAGE III, 3
STAGE IV, 1
STAGE IV, 0
STAGE IV, 1
STAGE IV, 0
0
1
2
3
4
5
6
7
31-40 41-50 51-60 >60
STAGE II STAGE III  STAGE IV
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STAGE WITH GRADE OF THE TUMOUR 
 
 
 
STAGE COMPARISON WITH GRADE OF THE TUMOUR 
  
 
GRADE I GRADE II 
GRADE 
III 
Valid STAGE II 1 9 2 
  STAGE III 0 15 1 
  STAGE IV 0 1 1 
  
 
      
 
Grade II appears to be common in all stages of ca breast. 
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6.DISCUSSION: 
 
1. Insulin resistance as documented by increased fasting insulin levels was 
found in 5 out of 29 patients , which accounts to 17 %,which is slightly lower 
than a study conducted at korea,which showed 26.4% prevalence of insulin 
resistance and was associated with larger tumours. Another study from Italy 
shows 46.95 % resistance with advanced breast cancers and with poor survival 
rates. This insists the need for this study in mass populations to screen for 
insulin resistance. 
2. The incidence of triple negative breast cancer is 34% present which is slightly 
higher when compared to other studies. 
3. The incidence of carcinoma breast is found to be most common in the age 
group of 41-50, with an almost equal incidence in 31-40 years. There seems to 
be a shifting trend of carcinoma breast in younger patients 
4. The earliest age being 32 yrs & the other extreme being 76 yrs. 
5. Mean age group is 49.66. 
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6. Insulin resistance was found more in women < 50 yrs of age(3 /5),in the 
analyzed cohort of patients. 
7. Its prevalence was more in post menopausal women, with an almost equal 
incidence in premenopausal women. 
8. It was associated with > 2 cm lesion 
9. Patients with insulin resistance (5/29) had node positive disease 
10. Insulin resistance is found  in patients with ER negative, PR negative 
disease 
11. Prevalence of HER 2 neu positivity is found more in patients with insulin 
resistance 
12. Three out of five patients who had insulin resistance had neoadjuvant 
chemotherapy prior to modified radical mastectomy. 
13. Stage III breast cancer is common among all age groups(55.12%)  
14. Grade II is found to be common in all stages of tumour. 
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7.CONCLUSION: 
Insulin resistance was found among 17 percent of the study population, which is 
slightly less than other published studies. 
Out of them, 60 percent had   ER NEGATIVE , PR NEGATIVE , & HER 2 neu 
positive  disease, and 60 percent of the women who had insulin resistance  had 
locally advanced breast cancer and underwent neoadjuvant chemotherapy 
followed by mastectomy. 
The study states that, insulin resistance which is considered a risk factor for 
many cancers, including carcinoma breast, might be prevalent in patients with 
normal glucose levels and in the absence of any symptoms. Screening them  
may be useful in identifying this cohort of patients and treating them with 
tailored  insulin resistance lowering agents like metformin which was found to 
have anti tumourogenic activity , as well as complete pathological response 
.One of the published articles documents decrease in local recurrence & distant 
metastasis in patients treated with insulin resistance lowering agents. 
Further studies are needed in asian population to analyse the outcomes of 
treatment with insulin resistance lowering agents which can potentially increase 
our knowledge in exploiting all modalities which could improve life of these 
patients and have a survival benefit. 
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RECOMMENDATIONS : 
Screening of carcinoma breast patients for insulin resistance ,with fasting 
insulin levels & fasting glucose levels which might help in identifying them at 
the earliest. 
In our study, the inability to identify breast cancer patients at the earliest might 
suggest ignorance  and lack of awareness of our people to the wide spread 
screening tests & proactive campaign about breast cancer.To improve and 
strengthen our screening tests for detecting carcinoma breast at an early stage. 
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                                                   MASTER CHART 
 
 
 
 
 
S.NO AGE IP NO SIDE QUADRANTSTAGING FASTING INSULIN LEVELS FBS
1 36 1726920 left UOQ II B 33 98
2 46 1739031 right UOQ II B 7.39 76
3 70 1738795 left UIQ IIIB 8.05 93
4 55 1746820 right RA IIIB 8.93 94
5 53 1745703 left UIQ IIB 4.94 85
6 45 1746464 right UOQ IIIA 8.24 102
7 76 1745437 right RA IIA 3.36 89
8 65 1740717 left UOQ IIB 7.42 108
9 60 1746870 left RA IV 7.69 79
10 43 1738504 left UOQ IIIB 5.37 88
11 45 1738441 right UOQ IIB 13 78
12 56 1757496 right UOQ IIB 53.49 84
13 50 1750138 right UOQ IIIA 8.32 76
14 32 1750624 left UOQ IIIA 4.46 92
15 40 1724636 left LIQ IV 11.04 84
16 73 11 right UOQ IIIA 9.92 106
17 38 1736976 left RA IIB 3.62 92
18 45 1745372 left UIQ IIIA 9.76 96
19 60 1734967 right UOQ IIIB 2.29 82
20 48 1737567 left UIQ IIIA 8.53 104
21 38 1746833 left UOQ IIIA 3.69 81
22 65 1738276 left UOQ IIIA 38.96 90
23 41 1754398 right UOQ IIA 42.33 72
24 AVARANJI 49 1702138 T3N1M0 right UOQ IIIA 28.52 114 GRADE II INVASIVE NE,NE,PO NEO ADJUVANT/mrm
25 MALA 35 1758535 T3N1M0 right UOQ IIIA 5.03 94 GRADE II INVASIVE PO,PO,NE neoadjuvant
26 SUBAITHA 39 1753949 T3N1M0 RIGHT UOQ IIIA 4.55 74 GRADE II INVASIVE PO,NE,NE neoadjuvant
27 zeenath begamee 54 1757757 T3N1M0 RIGHT UOQ IIIA 3.58 71 GRADE II INVASIVE NE,NE,NE NEOADJUVANT
28 mary 48 1748536 T2N0M0 left UOQ IIA 2.47 89 POSTMENOPAUSAL GRADE II INVASIVE PO,NE,PO MRM
29 RAMZAN BEE 35 1746276 T2N0M0 LEFT UIQ IIA 6.93 93 PREMENOPAUSAL GRADE II INVASIVE NE,NE,NE MRM
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